Atea Pharmaceuticals
AVIR
105 hedge funds and large institutions have $188M invested in Atea Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 37 reducing their positions, and 21 closing their positions.
2.72% more ownership
Funds ownership: 64.59% → 67.32% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 37
7% less funds holding
Funds holding: 113 → 105 (-8)
15% less capital invested
Capital invested by funds: $220M → $188M (-$32M)
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
94% less call options, than puts
Call options by funds: $297K | Put options by funds: $5.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Almitas Capital
Santa Monica,
California
|
+$4.81M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$3.13M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.45M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.49M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.62M |
| 2 |
Millennium Management
New York
|
-$860K |
| 3 |
BlackRock
New York
|
-$458K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$439K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$403K |
AVIR Hedge Fund Activity: Q2 2024 in Review
105 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q2 2024, worth a combined $188M — down 15% from $220M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AVIR and 13 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 36 added.
The largest buyer was Almitas Capital, opening a new position worth an estimated $4.81M. The largest seller was EcoR1 Capital, cutting an estimated $2.62M.
- 105 institutional investors held Atea Pharmaceuticals (AVIR) as of Q2 2024, down from 113 in Q1 2024.
- Funds reported $188M of Atea Pharmaceuticals stock for Q2 2024, down 15% quarter-over-quarter.
- 13 funds opened new Atea Pharmaceuticals positions in Q2 2024 and 21 closed out, a net change of -8 holders.
- The largest Atea Pharmaceuticals buyer in Q2 2024 was Almitas Capital, an estimated $4.81M added.
- The largest Atea Pharmaceuticals seller in Q2 2024 was EcoR1 Capital, an estimated $2.62M sold.
Based on aggregated 13F filings for Q2 2024.